Here are some steps labs may want to take in the wake of the 2022 National Health Care Fraud Enforcement Action.
Danielle H. Tangorre discusses key takeaways for labs from the DOJ’s recent nationwide takedown of $1.2 billion in alleged schemes.
Last week saw a takedown of $1.2B worth of alleged fraud schemes involving labs, genetic testing, and telemedicine.
First Special Fraud Alert in nearly two years cites six red flags of suspect arrangements with telehealth companies.
BioReference Health LLC and its parent company have agreed to pay $9.85 million to resolve alleged violations of the False Claims Act.